NVS vs PFE
Novartis AG and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NVS | PFE |
|---|---|---|
| Revenue | $54.5B | $62.6B |
| Net income | $14.0B | $7.8B |
| Gross margin | 78.8% | 74.3% |
| Net margin | 25.6% | 12.4% |
| Return on equity | 31.0% | 8.9% |
| Diluted EPS | $7.15 | $1.36 |
| Dividend / share | — | $1.72 |
| Payout ratio | — | — |
| Free cash flow | $17.6B | $9.1B |
| Equity | $46.1B | $86.5B |
| Net debt / equity | 0.37× | 0.73× |
| Current ratio | 1.12× | 1.16× |
| Revenue CAGR 5y | 2.3% | 8.5% |
| Profit CAGR 5y | 11.6% | −3.2% |
NVS and PFE book revenue within 15% of each other, and keeps more of each dollar of revenue as profit (25.6% against 12.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NVS | PFE |
|---|---|---|
| FY2025 | $54.5B | $62.6B |
| FY2024 | $50.3B | $63.6B |
| FY2023 | $45.4B | $59.6B |
| FY2022 | $42.2B | $101.2B |
| FY2021 | $42.8B | $73.6B |
| FY2020 | $48.7B | $41.7B |
| FY2019 | $47.5B | $40.9B |
| FY2018 | $44.8B | $40.8B |
| FY2017 | $42.4B | $52.5B |
| FY2016 | $48.5B | $52.8B |
Net income by year
Bottom line
| Fiscal year | NVS | PFE |
|---|---|---|
| FY2025 | $14.0B | $7.8B |
| FY2024 | $11.9B | $8.0B |
| FY2023 | $14.8B | $2.1B |
| FY2022 | $7.0B | $31.4B |
| FY2021 | $24.0B | $22.0B |
| FY2020 | $8.1B | $9.2B |
| FY2019 | $11.7B | $16.0B |
| FY2018 | $12.6B | $11.2B |
| FY2017 | $7.7B | $21.3B |
| FY2016 | $6.7B | $7.2B |
Advertisement
AdSense · Rectangle 336×280